Alnylam Pharmaceuticals (ALNY) P/S ratio

P/S ratio today
5.7×

Alnylam Pharmaceuticals (ALNY) trades at 5.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 14.4×. That is 7.9% higher than the 13.4× of fiscal 2024. Figures as of 18 Nov 2026, 09:08 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
5.7×
P/S ratio, fiscal 2025
14.4×
Change on fiscal 2024
+7.9%
Highest on record
57.3×fiscal 2019
Lowest on record
13.1×fiscal 2023
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Alnylam Pharmaceuticals P/S ratio, in more detail

Today's figure is 60.6% below the fiscal 2025 year-end.

Across the 7 fiscal year-ends on record (2019–2025), the highest was 57.3× in fiscal 2019 and the lowest 13.1× in fiscal 2023. Today's P/S ratio is at or below every one of the 7 fiscal year-ends on record; their median is 23.8×.

History · 7 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Alnylam Pharmaceuticals P/S ratio, year by year

Alnylam Pharmaceuticals (ALNY) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today5.7×—$156.50—
202514.4× 7.9% up$397.65$27.58
202413.4× 2.2% up$235.31$17.61
202313.1× 53.1% down$191.41$14.64
202227.9× 17.2% up$237.65$8.53
202123.8× 21.5% down$169.58$7.13
202030.3× 47.0% down$129.97$4.29
201957.3×—$115.17$2.01
2018——$72.91—
2017——$127.05—
2016——$37.44—
2015——$94.14—
2014——$97.00—
2013——$64.30—
2012——$18.25—
2011——$8.15—
2010——$9.86—
2009——$17.62—
2008——$24.73—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

P/S ratio at health care companies of similar size

P/S ratio of Alnylam Pharmaceuticals and comparable companies
CompanyP/S ratio
Tenet Healthcare THC1.1×
Guardant Health GH19.7×
Alnylam Pharmaceuticals ALNY5.6×
Zimmer Biomet Holdings ZBH2.3×
Medpace Holdings MEDP7.2×

Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.

More on ALNY

Alnylam Pharmaceuticals, figure by figure

Alnylam Pharmaceuticals (ALNY) overview: price, valuation and scorecardAll health care companies by market value

Alnylam Pharmaceuticals P/S ratio: questions and answers

What is Alnylam Pharmaceuticals's P/S ratio?

Alnylam Pharmaceuticals (ALNY) trades at 5.7× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 14.4×. That is 7.9% higher than the 13.4× of fiscal 2024.

Is Alnylam Pharmaceuticals's P/S ratio high or low compared with its own history?

Today's P/S ratio is at or below every one of the 7 fiscal year-ends on record; their median is 23.8×.

What are the highest and lowest P/S ratio figures on record for Alnylam Pharmaceuticals?

Across the 7 fiscal year-ends on record (2019–2025), the highest was 57.3× in fiscal 2019 and the lowest 13.1× in fiscal 2023.

How is Alnylam Pharmaceuticals's P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Alnylam Pharmaceuticals it is on record here for 7 fiscal years, 2019 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Alnylam Pharmaceuticals (ALNY) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ALNY/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.